Vitamin K2 supplier NattoPharma sponsored a survey in which a significant percentage of respondents were interested in maintaining arterial health.
Photo © iStockphoto.com/jasminam
A new survey on 380 consumers indicates that a significant percentage are interested in maintaining arterial health. Up to 35% of those surveyed said they were very concerned that hardening of arteries would negatively impact their heart health, while 67% said they would take a supplement to reduce the chances of arteries hardening. They said they would do this if the supplement had no side effects and was cost-comparable with other heart-health supplements.
Discovery Research Group conducted the survey in October 2015 on behalf of NattoPharma USA Inc. (Metuchen, NJ), a supplier of vitamin K2 MK7 ingredients. Last year, the company announced the first study (three-year; 244 subjects) showing that supplementing with NattoPharma’s MenaQ7 ingredient improved arterial stiffness in postmenopausal women.
In the recent survey, 25% of respondents identified themselves as having a condition associated with heart disease, while 40% had someone in their immediate family with a condition associated with heart disease; of those (the survey respondents or their family members), 84% were currently taking a prescription medicine and 44% took a supplement. Also, among 30- to 40-year-olds surveyed, supplementation was named the number-one action respondents would take if they developed a heart disease. Overall, on a scale of 1–7, 62% of survey respondents rated their level of concern about heart health overall as 5 or greater.
“Just over one-third of survey participants ranked ‘hardening of arteries’ as one of the top-three risk factors associated with heart disease,” said Eric Anderson, senior vice president of global sales and marketing, NattoPharma, in a press release announcing the results. He added that MenaQ7 “not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.
Recent review makes the case for testing omega-3 fatty acid levels in humans
May 23rd 2024The article commissioned by The Global Organization for EPA and DHA Omega-3s (GOED) reviewed the state of omega-3 fatty acid testing, highlighting the value of testing and the commercially available options for diagnostic testing.
Epax launches concentrated oil that combines omegas 3, 9, and 11
May 10th 2024The blend of long-chain polyunsaturated fatty acids and long-chain monounsaturated fatty acids combines the heart and brain health benefits of omegas-3s with the skin and metabolic health benefits of omegas 9 and 11.